You are here: Home > Prescription(RX) Drugs > O > Oxycodone Hydrochloride And Ibuprofen (Barr Laboratories Inc.)|
OXYCODONE HYDROCHLORIDE AND IBUPROFEN
oxycodone hydrochloride and
ibuprofen tablet, film coated
----------OXYCODONE HYDROCHLORIDE AND IBUPROFEN TABLETS CII
• NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS).
• Oxycodone HCl and ibuprofen tablets are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
• NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS).
Each combination oxycodone HCl and ibuprofen tablet contains 5 mg oxycodone hydrochloride, USP and 400 mg ibuprofen, USP.
Oxycodone HCl and ibuprofen tablets are supplied in a fixed combination tablet form for oral administration and combines the opioid analgesic agent, oxycodone HCl, with the non-steroidal anti-inflammatory (NSAID) agent, ibuprofen.
Oxycodone HCl is a centrally acting semisynthetic opioid analgesic. Its chemical name is 4,5α-Epoxy-14-hydroxy-3-methoxy-methylmorphinan-6-one hydrochloride. Its structural formula is:
Ibuprofen is a nonsteroidal anti-inflammatory drug with analgesic and antipyretic properties.
Its chemical name is (±)-2-(p-isobutylphenyl) propionic acid. Its structural formula is:
Inactive ingredients in oxycodone HCl and ibuprofen tablets include: butylated hydroxyanisole, carboxymethylcellulose sodium, hypromellose, microcrystalline cellulose, polydextrose, polyethylene glycol, povidone, sodium starch glycolate, titanium dioxide, triacetin, and vitamin E.
Oxycodone HCl Component
Oxycodone HCl is a semisynthetic opioid analgesic with multiple actions which involve the central nervous system and smooth muscle. The mechanism of action of oxycodone is not known but is thought to be related to its binding to opiate receptors in the central nervous system. In addition to analgesia, opioids may produce sedation and respiratory depression.
Ibuprofen is a nonsteroidal anti-inflammatory agent that possesses analgesic and antipyretic activities. Its mode of action, similar to other NSAIDs, is not completely understood, but is thought to be related to its inhibition of cyclooxygenase activity and prostaglandin synthesis. Ibuprofen is a peripherally acting analgesic. Ibuprofen does not have any known effects on opiate receptors.
Oxycodone is rapidly absorbed after single dose administration of oxycodone HCl and ibuprofen tablets. Maximum concentrations (Cmax) of oxycodone, ranging from 9.8 ng/mL to 11.7 ng/mL, are obtained within 1.3 hr to 2.1 hr after administration of oxycodone HCl and ibuprofen tablets. Repeated administration of oxycodone HCl and ibuprofen tablets every 6 hours results in approximately 50-65% increase in Cmax. In the presence of food, the bioavailability of oxycodone is slightly (25%) increased.
Ibuprofen is rapidly absorbed after oral administration of oxycodone HCl and ibuprofen tablets. Cmax values range from 18.5 mcg/mL to 34.3 mcg/mL and are reached 1.6 hr to 3.1 hr after oral administration of oxycodone HCl and ibuprofen tablets. Repeated administration of oxycodone HCl and ibuprofen tablets every 6 hours does not result in any accumulation of ibuprofen. The bioavailability of ibuprofen is not altered in the presence of food.
Oxycodone binding to protein in serum is approximately 45%.
Ibuprofen is extensively bound to plasma proteins (99%).
Oxycodone is metabolized in the liver by means of N-demethylation and O-demethylation, 6-ketoreduction and glucuronidation. The major circulating metabolite is noroxycodone, which possesses weak analgesic activity.
Oxymorphone, the end product of O-demethylation, has analgesic activity but is present in the plasma at low concentrations. Metabolism of oxycodone to oxymorphone occurs via CYP2D6.
Ibuprofen is present as a racemate and following absorption, it undergoes interconversion in the plasma from the R-isomer to the S-isomer.
Both the R- and S- isomers are metabolized to two primary metabolites: (+)-2-4'-(2-hydroxy-2-methyl-propyl) phenyl propionic acid and (+)-2-4'-(2-carboxypropyl) phenyl propionic acid, both of which circulate in the plasma at low levels relative to the parent.
Oxycodone is eliminated from the systemic circulation with half life (T½) values ranging from 3.1 hr to 3.7 hr after single dose administration of oxycodone HCl and ibuprofen tablets. Urinary excretion of unchanged oxycodone amounts to approximately 4% of the administered oxycodone dose.
Ibuprofen is eliminated from the systemic circulation with half life (T½) values ranging from 1.8 hr to 2.6 hr after single dose administration of oxycodone HCl and ibuprofen tablets. Urinary excretion of unchanged ibuprofen is minimal (less than 0.2% of administered ibuprofen dose).
There are no gender effects on the pharmacokinetics of oxycodone or ibuprofen after administration of oxycodone HCl and ibuprofen tablets.
The effects of age on the pharmacokinetics of oxycodone and ibuprofen after administration of oxycodone HCl and ibuprofen tablets have not been evaluated.
When either drug was administered alone, the pharmacokinetics of oxycodone and ibuprofen were similar in elderly subjects, compared to young healthy subjects.
The pharmacokinetics of oxycodone and ibuprofen after administration of oxycodone HCl and ibuprofen tablets have not been evaluated in a pediatric population.
The effects of renal impairment on the pharmacokinetics of oxycodone and ibuprofen after administration of oxycodone HCl and ibuprofen tablets have not been evaluated.
Oxycodone HCl and ibuprofen tablets were investigated in three clinical studies. Two studies involving a total of 949 patients following dental surgery (removal of ipsilateral molars) and a third study of 456 patients following abdominal/pelvic surgery were conducted. In the three studies patients were administered a single dose of the oxycodone HCl and ibuprofen tablets, ibuprofen alone, oxycodone HCl alone or placebo for acute, moderate to severe pain.
In these single dose studies, oxycodone HCl and ibuprofen tablets produced greater efficacy than placebo and each of oxycodone HCl and ibuprofen tablets' individual components as measured by the magnitude of pain relief and the reduction in pain intensity through six hours. No multiple dose efficacy studies have been performed with oxycodone HCl and ibuprofen tablets.
INDICATIONS AND USAGE
Carefully consider the potential benefits and risks of oxycodone HCl and ibuprofen tablets and other treatment options before deciding to use oxycodone HCl and ibuprofen tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).
Oxycodone HCl and Ibuprofen Tablets are indicated for the short term (no more than 7 days) management of acute, moderate to severe pain.
Oxycodone HCl and ibuprofen tablets should not be administered to patients who have previously exhibited hypersensitivity to oxycodone HCl, ibuprofen, or any of oxycodone HCl and ibuprofen tablets' components.
Oxycodone HCl and ibuprofen tablets should not be administered in any situation where opioids are contraindicated. This includes patients with significant respiratory depression (in unmonitored settings or the absence of resuscitative equipment) and patients with acute or severe bronchial asthma or hypercarbia. Patients known to be hypersensitive to other opioids may exhibit cross-sensitivity to oxycodone. Oxycodone HCl and ibuprofen tablets are contraindicated in any patient who has or is suspected of having paralytic ileus.
Oxycodone HCl and ibuprofen tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe anaphylactoid reactions to NSAIDs, some of which were fatal, have been reported in such patients (see WARNINGS, Anaphylactoid Reactions, and PRECAUTIONS, Preexisting Asthma).
Oxycodone HCl and ibuprofen tablets are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
Cardiovascular Thrombotic Events
Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur.
There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does increase the risk of serious GI events (see WARNINGS, Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation).
Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10-14 days following CABG surgery found an increased incidence of myocardial infarction and stroke (see CONTRAINDICATIONS).
NSAIDs, including oxycodone HCl and ibuprofen tablets, can lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including oxycodone HCl and ibuprofen tablets, should be used with caution in patients with hypertension. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.
Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation
NSAIDs, including oxycodone HCl and ibuprofen tablets, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3 to 6 months, and in about 2 to 4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.
NSAIDs should be prescribed with extreme caution in those with a prior history of ulcer disease or gastrointestinal bleeding. Patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding who use NSAIDs have a greater than 10-fold increased risk for developing a GI bleed compared to patients with neither of these risk factors. Other factors that increase risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population.
To minimize the potential risk for an adverse GI event in patients treated with an NSAID, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high risk patients, alternate therapies that do not involve NSAIDs should be considered.
Misuse, Abuse and Diversion of Opioids
Oxycodone HCl and ibuprofen tablets contain oxycodone, which is an opioid agonist, and a Schedule II controlled substance. Opioid agonists have the potential for being abused and are sought by abusers and people with addiction disorders, and are subject to diversion.
Oxycodone HCl and ibuprofen tablets can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing oxycodone HCl and ibuprofen tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion (see DRUG ABUSE AND DEPENDENCE).
Oxycodone may produce dose-related respiratory depression by acting directly on the brain stem respiratory centers. Oxycodone HCl also affects the center that controls respiratory rhythm, and may produce irregular and periodic breathing. Respiratory depression occurs most frequently in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other agents that depress respiration. Oxycodone HCl and ibuprofen tablets should be used with extreme caution in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and in patients having substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression. In such patients, even usual therapeutic doses of oxycodone HCl and ibuprofen tablets may decrease respiratory drive to the point of apnea.
Oxycodone HCl and ibuprofen tablets, like all opioid analgesics, may cause severe hypotension in an individual whose ability to maintain blood pressure has been compromised by a depleted blood volume, or after concurrent administration with drugs such as phenothiazines or other agents which compromise vasomotor tone. Oxycodone HCl and ibuprofen tablets may produce orthostatic hypotension in ambulatory patients. Oxycodone HCl and ibuprofen tablets, like all opioid analgesics, should be administered with caution to patients in circulatory shock, since vasodilatation produced by the drug may further reduce cardiac output and blood pressure.
Head Injury and Increased Intracranial Pressure
The respiratory depressant effects of opioids and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, intracranial lesions or a pre-existing increase in intracranial pressure. Furthermore, opioids produce adverse reactions that may obscure the clinical course of patients with head injuries.
Acute Abdominal Conditions
The administration of opioids may obscure the diagnosis or clinical course of patients with acute abdominal conditions.
Anaphylactoid reactions may occur in patients without known prior exposure to oxycodone HCl and ibuprofen tablets. Oxycodone HCl and ibuprofen tablets should not be given to patients with the aspirin triad or a history of angioedema. The triad typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs. Fatal reactions to NSAIDs have been reported in such patients (see CONTRAINDICATIONS and PRECAUTIONS, Preexisting Asthma). Emergency help should be sought when anaphylactoid reaction occurs.
Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.
Advanced Renal Disease
In patients with advanced kidney disease, treatment with oxycodone HCl and ibuprofen tablets is not recommended. No information is available from controlled clinical studies regarding the use of oxycodone HCl and ibuprofen tablets in patients with advanced renal disease. However, if oxycodone HCl and ibuprofen tablets therapy must be initiated, due to the NSAID component, close monitoring of the patient’s kidney function is advisable (see WARNINGS, Renal Effects).
NSAIDs, including oxycodone HCl and ibuprofen tablets, can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.
Starting at 30 weeks gestation, oxycodone HCl and ibuprofen tablets, and other NSAIDs, should be avoided by pregnant women as premature closure of the ductus arteriosus may occur.
Oxycodone HCl and ibuprofen tablets cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.
The pharmacological activity of oxycodone HCl and ibuprofen tablets in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.
Special Risk Patients
As with any opioid analgesic agent, oxycodone HCl and ibuprofen tablets should be used with caution in elderly or debilitated patients, and those with severe impairment of hepatic, pulmonary or renal function, hypothyroidism, Addison's disease, acute alcoholism, convulsive disorders, CNS depression or coma, delirium tremens, kyphoscoliosis associated with respiratory depression, toxic psychosis, prostatic hypertrophy or urethral stricture. The usual precautions should be observed and the possibility of respiratory depression, postural hypotension, and altered mental states should be kept in mind.
Use in Pancreatic/Biliary Tract Disease
Oxycodone HCl and ibuprofen tablets may cause spasm of the sphincter of Oddi and should be used with caution in patients with biliary tract disease, including acute pancreatitis. Opioids like oxycodone HCl and ibuprofen tablets may cause increases in the serum amylase level.
Oxycodone suppresses the cough reflex; as with other opioid containing products, caution should be exercised when oxycodone HCl and ibuprofen tablets is used postoperatively and in patients with pulmonary disease.
Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including ibuprofen as found in oxycodone HCl and ibuprofen tablets. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported.
A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with oxycodone HCl and ibuprofen tablets. If clinical signs and symptoms consistent with liver disease develop, or if systematic manifestations occur (e.g., eosinophilia, rash, etc.), oxycodone HCl and ibuprofen tablets should be discontinued.
Anemia is sometimes seen in patients receiving NSAIDs, including ibuprofen as found in oxycodone HCl and ibuprofen tablets. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including ibuprofen, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia.
NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving oxycodone HCl and ibuprofen tablets who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored. Patients previously treated with NSAIDs and currently using oxycodone HCl and ibuprofen tablets should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia.
Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm, which can be fatal. Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, oxycodone HCl and ibuprofen tablets should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with pre-existing asthma.
Aseptic meningitis with fever and coma has been observed on rare occasions in patients on ibuprofen as found in oxycodone HCl and ibuprofen tablets. Although it is probably more likely to occur in patients with systemic lupus erythematosus and related connective tissue diseases, it has been reported in patients who do not have an underlying chronic disease. If signs or symptoms of meningitis develop in a patient on oxycodone HCl and ibuprofen tablets, the possibility of its being related to ibuprofen should be considered.
Information for Patients
Because serious GI tract ulcerations and bleeding can occur without warning symptoms, physicians should monitor for signs or symptoms of GI bleeding. Patients on long-term treatment with NSAIDs should have their CBC and a chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or renal disease develop, systemic manifestations occur (e.g. eosinophilia, rash, etc.) or if abnormal liver tests persist or worsen, oxycodone HCl and ibuprofen tablets should be discontinued.
Oxycodone is metabolized in part to oxymorphone via the cytochrome P450 isoenzyme CYP2D6. While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs and antidepressants), such blockade has not yet been shown to be of clinical significance with this agent. However, clinicians should be aware of this possible interaction.
The concurrent use of anticholinergics with oxycodone preparations may produce paralytic ileus.
Patients receiving narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics or other CNS depressants (including alcohol) concomitantly with oxycodone may exhibit an additive CNS depression. Interactive effects resulting in respiratory depression, hypotension, profound sedation, or coma may result if these drugs are taken in combination with the usual dosage of oxycodone. When such combined therapy is contemplated, the dose of one or both agents should be reduced.
Mixed Agonist/Antagonist Opioid Analgesics
Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) should be administered with caution to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone. In this situation, mixed agonist/antagonist analgesics may reduce the analgesic effect of oxycodone and/or may precipitate withdrawal symptoms in these patients.
Monoamine Oxidase Inhibitors (MAOIs)
MAOIs have been reported to intensify the effects of at least one opioid drug causing anxiety, confusion and significant depression of respiration or coma. The use of oxycodone is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.
Neuromuscular Blocking Agents
Oxycodone, as well as other opioid analgesics, may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.
Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking oxycodone HCl and ibuprofen tablets concomitantly with ACE-inhibitors.
When oxycodone HCl and ibuprofen tablets are administered with aspirin, its protein binding is reduced, although the clearance of free oxycodone HCl and ibuprofen tablets is not altered. The clinical significance of this interaction is not known; however as with other products containing NSAIDs, concomitant administration of oxycodone HCl and ibuprofen tablets and aspirin is not generally recommended because of the potential of increased adverse effects.
Ibuprofen has been shown to reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with oxycodone HCl and ibuprofen tablets the patient should be observed closely for signs of renal failure (see WARNINGS, Renal Effects), as well as diuretic efficacy.
Ibuprofen has been shown to produce an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when oxycodone HCl and ibuprofen tablets and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
Ibuprofen, as well as other NSAIDs, has been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that ibuprofen could enhance the toxicity of methotrexate. Caution should be used when oxycodone HCl and ibuprofen tablets are administered concomitantly with methotrexate.
Carcinogenicity, Mutagenicity and Impairment of Fertility
Studies to evaluate the potential effects of the combination of oxycodone and ibuprofen on carcinogenicity and mutagenicity have not been conducted.
Oxycodone HCl was not genotoxic in the following assays: Ames bacterial mutation assay, chromosomal aberrations in cultured human lymphocytes, and in vivo mouse micronucleus assay in mice.
There was no evidence of impairment of fertility in either male or female Sprague-Dawley rats administered oxycodone HCl; ibuprofen up to (1:80 mg/kg/day) which is equivalent to 0.5 times the maximum recommended human daily dose (MRHD) (20:1600 mg/day) on a body surface area (mg/m2) basis.
Pregnancy Category C prior to 30 weeks gestation; Category D starting at 30 weeks gestation
Starting at 30 weeks gestation, oxycodone HCl and ibuprofen tablets, and other NSAIDs, should be avoided by pregnant women as premature closure of the ductus arteriosus in the fetus may occur. Oxycodone HCl and ibuprofen tablets can cause fetal harm when administered to a pregnant woman starting at 30 weeks gestation. If oxycodone HCl and ibuprofen tablets, and other NSAIDs, are used during this time period in pregnancy, the patient should be apprised of the potential hazard to a fetus. There are no adequate and well-controlled studies in pregnant women. Prior to 30 weeks gestation, oxycodone HCl and ibuprofen tablets should be used during pregnancy only if the potential benefit justifies the risk to the fetus.
Animal studies to assess the potential effects of the combination of oxycodone and ibuprofen on embryo-fetal development were conducted in the rat and rabbit model.
Pregnant rats were treated by oral gavage with combination doses of oxycodone/ibuprofen mg/kg/day (0.25:20, 0.5:40, 1:80, or 2:160) on days 7 to 16 of gestation. There was no evidence for developmental toxicity or teratogenicity at any dose, although maternal toxicity was noted at doses of 0.5:40 and above. The highest dose tested in the rat (2:160 mg/kg/day) is equivalent to the maximum recommended human daily dose (20:1600 mg/day) on a body surface area (mg/m2) basis. This dose was associated with maternal toxicity (death, clinical signs, decreased BW).
Pregnant rabbits were treated by oral gavage with combination doses of oxycodone/ibuprofen (0.38:30, 0.75:60, 1.5:120 or 3:240 mg/kg/day) on gestation days 7 to 19. Oxycodone/ibuprofen treatment was not teratogenic under the conditions of the assay. Maternal toxicity was noted at doses of 1.5:120 (reduced body weight and food consumption) and 3:240 mg/kg/day (mortality). The NOAEL for maternal toxicity, 0.75:60 mg/kg/day, is 0.75 fold the proposed maximum daily human dose based upon the body surface area. Developmental toxicity, as evidenced by delayed ossification and reduced fetal body weights, was noted at the highest dose, which is approximately 3 times the MRHD on a mg/m2 basis, and is likely due to maternal toxicity. The fetal no adverse effect level (NOAEL) of 1.50:120 mg/kg/day is approximately 1.5 times the MRHD on a mg/m2 basis.
In a pre- and post-natal development study conducted in rats, there was increased mortality of pups born to dams dosed with 0.5:40 mg/kg/day oxycodone/ibuprofen and above which is equivalent to 0.25 times of the MRHD (20:1600 mg/day) on a body surface area (mg/m2) basis. There was an increase in stillborn F1 pups and decrease in mean pup weight in dams dosed with 1:80 mg/kg/day oxycodone/ibuprofen, which is 0.5 times the MRHD (20:1600 mg/day) on a body surface area (mg/m2) basis.
Because of the known effects of NSAIDs on the fetal cardiovascular system (closure of the ductus arteriosus), use in pregnancy, particularly late pregnancy should be avoided.
Babies born to mothers who have been taking opioids regularly prior to delivery will be physical dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. There is no consensus on the best method of managing withdrawal.
Labor and Delivery
Oxycodone HCl and ibuprofen tablets should not be used during the third trimester of pregnancy due to the potential for ibuprofen to inhibit prostaglandin synthetase which may prolong pregnancy and inhibit labor. Oxycodone is not recommended for use in women during and immediately prior to labor and delivery because oral opioids may cause respiratory depression in the newborn.
In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred. The effects of oxycodone HCl and ibuprofen tablets on labor and delivery in pregnant women are unknown.
It is not known whether oxycodone HCl and ibuprofen tablets are excreted in human milk. Oxycodone is excreted in human milk. Withdrawal symptoms and/or respiratory depression have been observed in neonates whose mothers were taking narcotic analgesics during pregnancy. Although adverse effects in the nursing infant have not been documented, withdrawal can occur in breastfeeding infants when maternal administration of an opioid analgesic is discontinued. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from oxycodone HCl and ibuprofen tablets, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
In the placebo-controlled, clinical studies of pain following dental surgery, 109 patients between the ages of 14 and 17 years were administered a single dose of oxycodone HCl and ibuprofen tablets. No apparent differences were noted in the safety of oxycodone HCl and ibuprofen tablets in patients below and above 17 years of age. Oxycodone HCl and ibuprofen tablets has not been studied in patients under 14 years of age. Safety and effectiveness in pediatric patients below the age of 14 have not been established.
Of the total number of subjects in clinical studies of oxycodone HCl and ibuprofen tablets, 89 patients were 65 and over, while 37 patients were 75 and over. No overall differences in safety were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
However, because the elderly may be more sensitive to the renal and gastrointestinal effects of non-steroidal anti-inflammatory agents as well as possible increased risk of respiratory depression with opioids, extra caution should be used when treating the elderly with oxycodone HCl and ibuprofen tablets.
Listed below are the adverse event incidence rates from single dose analgesia trials in which a total of 2437 patients received either oxycodone HCl and ibuprofen tablets, ibuprofen (400 mg), oxycodone HCl (5 mg), or placebo. Adverse event information is also provided from an additional 334 patients who were exposed to oxycodone HCl and ibuprofen tablets in a multiple dose analgesia trial, without placebo or active component comparison arms, given up to four times daily for up to 7 days.
Adverse events that were reported by at least 1% of patients taking oxycodone HCl and ibuprofen tablets but were observed at a greater incidence in the placebo treated patients were fever, headache and pruritus.
Adverse events that occurred in less than 1% and in at least two oxycodone HCl and ibuprofen tablets treated patients in Single Dose studies not listed above include the following:
Adverse events that occurred in the Multiple Dose study in at least 2% of patients treated with oxycodone HCl and ibuprofen tablets include the following:
constipation (4.5%), diarrhea (2.1%), dyspepsia (2.1%), nausea (25.4%), vomiting (4.5%).
dizziness (19.2%), somnolence (17.4%).
Adverse events that occurred in less than 2% of and at least two oxycodone HCl and ibuprofen tablets treated patients in the Multiple Dose study not listed previously include the following:
DRUG ABUSE AND DEPENDENCE
Oxycodone HCl and ibuprofen tablets contain oxycodone, which is a mu-opioid agonist with an abuse liability similar to other opioid agonists and is a Schedule II controlled substance. Oxyco- done HCl and ibuprofen tablets, and other opioids used in analgesia, can be abused and are subject to criminal diversion.
Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. Drug addiction is a treatable disease utilizing a multidisciplinary approach, but relapse is common.
“Drug seeking” behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). “Doctor shopping” to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction.
Abuse and addiction are separate and distinct from physical dependence and tolerance. Physical dependence usually assumes clinically significant dimensions only after several weeks of continued opioid use, although a mild degree of physical dependence may develop after a few days of opioid therapy. Tolerance, in which increasingly large doses are required in order to produce the same degree of analgesia, is manifested initially by a shortened duration of analgesic effect, and subsequently by decreases in the intensity of analgesia. The rate of development of tolerance varies among patients. Physicians should be aware that abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Oxycodone HCl and ibuprofen tablets, like other opioids, may be diverted for non-medical use. Record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.
Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.
Following an acute overdosage, toxicity may result from oxycodone and/or ibuprofen.
Signs and Symptoms
Acute overdosage with oxycodone may be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, or hypotension. In severe cases death may occur.
The toxicity of ibuprofen overdose is dependent on the amount of drug ingested and the time elapsed since ingestion, although individual response may vary, necessitating individual evaluation of each case. Although uncommon, serious toxicity and death have been reported in the medical literature with ibuprofen overdosage. The most frequently reported symptoms of ibuprofen overdose include abdominal pain, nausea, vomiting, lethargy, and drowsiness. Other central nervous system symptoms include headache, tinnitus, CNS depression, and seizures. Cardiovascular toxicity, including hypotension, bradycardia, tachycardia, and atrial fibrillation, have also been reported.
In the treatment of opioid overdosage, primary attention should be given to the re-establishment of a patent airway and institution of assisted or controlled ventilation. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory shock and pulmonary edema accompanying overdose, as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation. The narcotic antagonist naloxone hydrochloride is a specific antidote against respiratory depression, which may result from overdosage or unusual sensitivity to narcotics including oxycodone. An appropriate dose of naloxone hydrochloride should be administered intravenously with simultaneous efforts at respiratory resuscitation. Since the duration of action of oxycodone may exceed that of the naloxone, the patient should be kept under continuous surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. Management of hypotension, acidosis and gastrointestinal bleeding may be necessary. In cases of acute overdose, the stomach should be emptied through ipecac-induced emesis or gastric lavage. Orally administered activated charcoal may help in reducing the absorption and reabsorption of ibuprofen. Emesis is most effective if initiated within 30 minutes of ingestion. Induced emesis is not recommended in patients with impaired consciousness or overdoses greater than 400 mg/kg of the ibuprofen component in children because of the risk for convulsions and the potential for aspiration of gastric contents.
DOSAGE AND ADMINISTRATION
Carefully consider the potential benefits and risks of oxycodone HCl and ibuprofen tablets and other treatment options before deciding to use oxycodone HCl and ibuprofen tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).
After observing the response to initial therapy with oxycodone HCl and ibuprofen tablets, the dose and frequency should be adjusted to suit an individual patient's needs.
For the management of acute moderate to severe pain, the recommended dose of oxycodone HCl and ibuprofen tablets is one tablet given orally.
Dosage should not exceed 4 tablets in a 24-hour period and should not exceed 7 days.
Oxycodone HCl and Ibuprofen Tablets, 5 mg/400 mg are available as white to off-white, modified capsule shaped, film-coated, scored tablets, debossed with stylized b/778 on the scored side, packaged in bottles of 100 tablets.
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
Dispense in a tight container as defined in the USP, with a child-resistant closure (as required).
KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
A Schedule CII Narcotic
TEVA PHARMACEUTICALS USA
Sellersville, PA 18960
Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
(See the end of this Medication Guide for a list of prescription NSAID medicines.)
What is the most important information I should know about medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?
NSAID medicines may increase the chance of a heart attack or stroke that can lead to death. This chance increases:
NSAID medicines should never be used right before or after a heart surgery called a “coronary artery bypass graft (CABG).”
NSAID medicines can cause ulcers and bleeding in the stomach and intestines at any time during treatment. Ulcers and bleeding:
The chance of a person getting an ulcer or bleeding increases with:
NSAID medicines should only be used:
What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?
NSAID medicines are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as:
Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)?
Do not take an NSAID medicine:
Tell your healthcare provider:
What are the possible side effects of Non-Steroidal Anti-Inflammatory Drugs
Get emergency help right away if you have any of the following symptoms:
Stop your NSAID medicine and call your healthcare provider right away if you
have any of the following symptoms:
These are not all the side effects with NSAID medicines. Talk to your healthcare provider or
pharmacist for more information about NSAID medicines.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Other information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
NSAID medicines that need a prescription
*Vicoprofen contains the same dose of ibuprofen as over-the-counter (OTC) NSAIDs, and is usually used for less than 10 days to treat pain. The OTC NSAID label warns that long term continuous use may increase the risk of heart attack or stroke.
This Medication Guide has been approved by the U.S. Food and Drug Administration.
TEVA PHARMACEUTICALS USA
Sellersville, PA 18960
PRINCIPAL DISPLAY PANEL
Revised: 03/2011 Barr Laboratories Inc.
Reproduced with permission of U.S. National Library of Medicine
Copyright © 2017
|Over-the-counter (OTC) Drugs|